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Abstract
Zygomycetes are increasingly reported as a cause of life-threatening invasive fungal infections in profoundly immunocompromised
patients and in those with diabetic ketoacidosis. Zygomycosis, typically presents as soft tissue, rhino-orbitocerebral, pulmonary or
disseminated disease and is characterized by rapid clinical progression and high mortality rates. Treatment with amphotericin B lipid
formulations in combination with surgery and, perhaps, the addition of caspofungin offers the best chance for survival; posaconazole, a
new antifungal triazole, is increasingly used for consolidation or maintenance therapy. Because of the poor prognosis of zygomycosis,
particularly in immunocompromised cancer patients, adjunctive treatments such as hyperbaric oxygen therapy, use of immunomodula-
tory cytokines, and in vivo iron starvation continue to be explored. However, although each of these modalities is based on a plausible
scientiﬁc rationale and has been helpful in the management of individual patients, there is no clinical evidence for their general effective-
ness as adjunctive treatments in patients with zygomycosis. Further experimental and clinical investigations are necessary to determine
whether and how these treatments can impact on outcome and to determine which patients and which types of infection may beneﬁt
from them.
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Introduction
Over the past decade, zygomycosis has been increasingly
recognized as an important invasive fungal infection, particu-
larly in patients with haematological malignancies, haemato-
poietic stem cell transplantation (HSCT), poorly controlled
diabetes mellitus, and those treated with the iron chelator,
deferoxamine. The agents of zygomycosis (Rhizopus, Mucor,
Rhizomucor, Cunninghamella and Absidia spp.) are a group
of biologically diverse, primarily opportunistic and mostly
airborne pathogens of wide ecological distribution. Infec-
tions in humans are characterized by aggressive growth
across all anatomical barriers with angioinvasion, thrombo-
sis, haemorrhagic infarction and extensive tissue necrosis
[1–8].
The major clinical manifestations of zygomycosis include
rhino-orbitocerebral, pulmonary and disseminated infection;
primary gastrointestinal and primary cutaneous infections are
less frequent [1]. Depending on the underlying condition, the
site of infection and the initiation of antifungal therapy, zygo-
mycosis is associated with high mortality rates in the range
of 35–70%, and close to 100% in disseminated disease with
cerebral involvement [9]. Current approaches to manage-
ment include the prompt initiation of antifungal chemother-
apy, surgical debridement as feasible, restoration of
immunologic or metabolic deﬁciencies, stabilization of the
infection during compromised host status, and treatment
until the resolution of all signs and symptoms [10]. Although
there is currently expert consensus that amphotericin B
(AmB) lipid complex or liposomal amphotericin B (L-AmB)
are ﬁrst choices for initial treatment, the optimal doses and
uses for targeting different body sites remain unclear [11].
An emerging, although non-approved, option for second-line,
consolidation or maintenance treatment is posaconazole and,
perhaps, the combination of AmB with caspofungin [12].
However, despite advances in both the understanding and
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management of zygomycosis, outcome remains poor and
adjunctive treatments continue to be explored.
In this article, we review the theoretical and experimental
foundations and clinical data on hyperbaric oxygen treatment
(HBOT), adjunctive use of cytokines, and iron depletion with
newer chelators as adjunctive treatments for zygomycosis.
Other adjunctive measures, such as intra-arterial, aerosolized
and intralesional administration of antifungal agents, or irriga-
tion of infected tissues with antiseptics or antifungals, are
not considered.
Hyperbaric Oxygen Treatment
The use of hyperbaric oxygen as adjunctive treatment for
zygomycosis has been reported since the 1970s [13–17].
Although HBOT has been recommended and used in an
extremely wide variety of medical conditions, the Undersea
and Hyperbaric Medical Society endorses its use in only a
few indications for which there is thought to be scientiﬁc
evidence or validated clinical experience and which are
accepted by the US Centers for Medicare and Medicaid Ser-
vices for reimbursement [18]. Pressurized hyperoxygenation
(i.e. exposure to oxygen at high ambient pressures) greatly
increases the oxygen transport capacity in blood and the
oxygen pressure gradient across capillary membranes,
thereby augmenting tissue oxygenation [19, 20]. This is
believed to be beneﬁcial in situations of hypoperfusion and
anaerobism, and is supported by experimental data that have
demonstrated direct antimicrobial activity, restoration or
enhancement of cellular defences, synergistic effects with
antimicrobials, and restoration or augmentation of tissue
repair [21,22]. During HBOT, 100% oxygen is administered
in a monoplace or multiplace chamber through masks, tightly
ﬁtting hoods or endotracheal tubes. Inside the chambers,
pressure is usually increased to c. 250–280 kPa, equivalent to
a depth of 15–18 m of water and resulting in a PaO2 of
approximately 1200–2000 mmHg. The recommended dura-
tion of a session (‘dive’) varies between 90–120 min with
periodic air breaks to minimize the risk of oxygen toxicity;
for longterm conditions, patients may receive 20–40 sessions
administered according to a once-per-day to three-times-
per-day schedule. The cost charged is USD 12 000–20 000
per 30 sessions [20].
Hyperbaric oxygen treatment is usually well tolerated and
is associated with a low risk of adverse events. In general, if
pressures exceed 300 kPa and the duration of treatment is
more than 120 min, central nervous system (CNS), pulmo-
nary, optic and middle ear symptoms may occur as a result
of oxygen toxicity [19]. Overall, severe CNS symptoms may
occur in 1–2% of patients, symptomatic reversible barotrau-
ma in 15–20%, pulmonary symptoms in 15–20% and revers-
ible blurred vision in up to 20% of patients. Untreated
pneumothorax represents the only absolute contraindication
for HBOT, whereas relative contraindications include a his-
tory of grand mal seizures, fever, congestion, emphysema,
severe maxillofacial/head damage and pregnancy [19].
Zygomycoses are acute, angioinvasive, necrotizing tissue
infections, that are characterized by invasion of blood ves-
sels, thrombosis, infarction, tissue hypoxia and lactic acidosis
[10]. HBOT has been shown to have direct antifungal activity
in vitro at pressures <10 atmospheres (atm) absolute that is
attributed to increased production of oxygen-based free
radicals under hyperoxic conditions [17]; fungal mutants lack-
ing antioxidant enzymes have an increased susceptibility to
killing by HBOT that may be restored by the induction of
antioxidant enzymes [23]. In addition, HBOT may have
several indirect antimicrobial effects, including reversal of
growth-promoting lactic acidosis, restoration of phagocytosis
and augmentation of the oxidative burst by polymorphonu-
clear leukocytes (PMLs), and enhancement of the antifungal
action of AmB [21,24]. Finally, HBOT contributes to tissue
healing by increasing tissue oxygen levels, restoring normal
ﬁbroblast function, increasing collagen deposition, and pro-
moting the secretion of inﬂammatory cytokines and angio-
genesis [21,25,26].
In vivo, in deferoxamine-treated CD-1 mice with experi-
mental disseminated zygomycosis, there was no added sur-
vival effect of HBOT as an adjunct to AmB, in comparison
with AmB plus placebo air treatment [27]. However, the
pressure used in these experiments (i.e. 2 atm absolute in
two daily sessions) was comparatively low and applied with-
out concomitant hyperoxygenation; moreover, an intra-
venous injection model may not be entirely representative of
deep tissue infection as observed in humans; thus, the results
of these experiments unfortunately remain inconclusive.
Data regarding the clinical efﬁcacy of HBOT in invasive
fungal infections are still limited. In an early retrospective
study of 13 patients with rhinocerebral zygomycosis, six of
whom received HBOT in addition to AmB and surgery, bet-
ter survival in patients receiving HBOT was observed [28].
Segal et al. recently reported on 14 patients with zygomyco-
sis or aspergillosis treated over a 12-year period with HBOT
as an adjunct to antifungal chemotherapy and surgery. Seven
of the patients survived and none experienced adverse
events related to HBOT [29]. A contemporary literature
review identiﬁed 28 cases in which zygomycosis was treated
adjunctively with HBOT [30]. Underlying conditions included
diabetes mellitus (61%), trauma (18%), haematological malig-
nancies (11%), alcoholic liver disease (7%) and there was
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treatment with systemic corticosteroids (3%), no underlying
disease (11%) of cases. The most commonly affected site of
infection was sino-orbitocerebral in 75% of patients, followed
by soft tissues (14%) and the lung (7%). Most of the patients
received two sessions of HBOT per day for 90–120 min at a
pressure of 2–3 atm absolute. In most patients, HBOT was
administered postoperatively (23/25 with surgery, 92%). All
but two patients also received antifungal treatment with
AmB. The overall survival rate at end of treatment was 86%.
Whereas survival was 94% in diabetes patients, it was poor
(one of three) in patients with haematological malignancies
or HSCT. There were no deaths among patients with trauma
or without underlying disease. All patients who died had
sino-orbitocerebral disease. Prolonged courses of hyperoxy-
genation (ten or more administrations) were associated with
higher survival [30]. The impressively high survival rate of
reported patients treated with adjunctive HBOT, however,
may have been biased by several factors. Most patients in
this series had correctable predisposing conditions; patients
who did not respond to HBOT may be under-reported in
the literature, and the improved survival rate among patients
who received extended sessions may represent a survival
bias as those who responded were more likely to continue
hyperoxygenation treatment [30].
Thus, although there appears to be a scientiﬁc rationale for
adjunctive HBOT in the treatment of zygomycosis, the clinical
evidence is only anecdotal and does not allow for conclusions
about its general clinical efﬁcacy, nor about host- or disease-
speciﬁc conditions of patients who might beneﬁt from it.
Adjunctive Cytokines
Although the antifungal activity of PMLs and macrophages
against Zygomycetes and the mechanisms involved in this
activity were elucidated some time ago, few new data exist
to enable better understanding of host defences against these
organisms and the role of cytokines [31].
Polymorphonuclear leukocytes and macrophages are well
known to constitute an important defensive mechanism
against the agents of zygomycosis [32], providing a rationale
for the use of granulocyte colony-stimulating factor (G-CSF),
granulocyte-macrophage colony-stimulating factor (GM-CSF),
and interferon-c (IFN-c) as adjunctive treatment beyond the
setting of granulocytopenia. G-CSF and GM-CSF have been
shown to increase phagocytosis, oxidative burst and fungi-
cidal activity of PMLs [33–37], and IFN-c to induce a T-
helper cell type 1 (Th1) immunological response that favours
resistance to invasive fungal infections and enhances PMLs’
antifungal activities [32,37,38].
Early experiments conducted to assess the ability of
G-CSF to enhance PML activity against opportunistic fungal
pathogens have demonstrated that G-CSF is able to
enhance PML-mediated killing of Rhizopus arrhizus and
induces a sustained respiratory burst in response to
extracts of the organisms, implicating a possible therapeutic
role for G-CSF as a response-modifying agent during infec-
tion [39]. A more recent series of experiments examined
the comparative antifungal function of PMLs against hyphae
of Rhizopus oryzae, Rhizopus microsporus and Absidia corymbif-
era, and evaluated the effects of IFN-c GM-CSF, alone or
combined, on PML antifungal function against these Zygo-
mycetes [31]. In this study, human PMLs had a reduced
capacity to mount an oxidative burst in response to both
Rhizopus species and to induce hyphal damage of these
Zygomycetes, in comparison with its response to A. cor-
ymbifera. However, IFN-c and GM-CSF augmented
PML-induced hyphal damage of all three Zygomycetes in a
time-dependent manner. Furthermore, treatment of PMLs
with the combination of cytokines enhanced the release of
TNF-a in response to R. microsporus and A. corymbifera, but
not in response to R. oryzae hyphae. By comparison, IFN-c
inhibited interleukin-8 (IL-8) release in response to hyphae
of the three Zygomycetes. The results of these experi-
ments suggest intergenus differences in host response to
Zygomycetes and a potential role for IFN-c and GM-CSF in
the management of invasive zygomycosis.
Granulocyte CSF and GM-CSF have been used in a limited
number of cases of zygomycosis as adjunctive treatment with
favourable outcomes [40,41]. Although individual patients
with extensive or refractory disease may beneﬁt from the
use of adjunctive cytokine treatment, further studies are
needed to assess the general utility of IFN-c, G-CSF or GM-
CSF as adjuncts to antifungal chemotherapy.
Iron Chelation Treatment
Iron is required by virtually all microbial pathogens for
growth and virulence. Patients with elevated levels of avail-
able serum iron are susceptible to infection by Zygomycetes,
but not necessarily to infection by other fungi [42,43]. Iron
metabolism plays an important role in infections with Zygo-
mycetes and, paradoxically, an iron chelator, deferoxamine,
has been found to promote zygomycosis. Deferoxamine, by
its speciﬁc chemical structure, acts as an iron xenosidero-
phore for Zygomycetes, explaining the clinical observation of
an association between zygomycosis and hypertransfusion
[44]. This observation is well supported by animal models
of experimental disseminated zygomycosis that uniformly
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demonstrate the detrimental effects of deferoxamine on
survival [44–47]. Indeed, a very comprehensive literature
analysis of the epidemiology, presentation and outcome of
zygomycosis revealed that zygomycosis occurring in the con-
text of deferoxamine treatment was associated with the
highest rate of disseminated infection compared with any
other underlying condition [9].
By contrast, however, newer chelators such as deferi-
prone and deferasirox do not act as siderophores, but have
been shown to have antifungal activity against Zygomycetes
in vitro and in vivo [48,49]. In experimental investigations
performed by Ibrahim et al., deferiprone had static activity
in vitro against R. oryzae at 24 h, but was fungicidal at 48 h of
incubation. In vivo, in diabetic ketoacidotic mice with dissemi-
nated R. oryzae infection, deferiprone was as effective as
L-AmB, improving survival and decreasing brain fungal bur-
den, and both drugs were more effective than placebo in
non-iron-overloaded animals. Administration of free iron
with deferiprone reversed protection, conﬁrming that the
mechanism of protection was iron chelation [50]. In a subse-
quent, exceedingly well designed series of experiments, the
authors demonstrated by molecular analysis effective iron
chelation from R. oryzae by deferasirox and fungicidal activity
in vitro against 28 of 29 clinical isolates of Mucorales at con-
centrations below clinically achievable serum levels. When
administered to diabetic ketoacidotic or neutropenic mice
with mucormycosis, deferasirox signiﬁcantly improved sur-
vival and decreased tissue fungal burden, with an efﬁcacy sim-
ilar to that of L-AmB. Deferasirox treatment also enhanced
the host inﬂammatory response to mucormycosis. Finally,
deferasirox synergistically improved survival and reduced tis-
sue fungal burden when combined with L-AmB.
These data collectively support the clinical investigation of
iron starvation as adjunctive therapy to improve outcomes in
cases of disseminated zygomycosis. To date, however, there
are only anecdotal clinical data on the use of deferasirox in
patients with invasive zygomycosis [51,52]. Although one case
report describes an immediate and striking effect of the
co-administration of deferasirox in a patient with rhino-
cerebral mucormycosis [51], Soummer et al. [52] reported
progressive tissue invasion and treatment failure in the case of
co-administered deferasirox in a patient with systemic intra-
abdominal and intrathoracic zygomycosis. Whether treatment
failure in the latter case reﬂected an already catastrophic
situation at baseline, or was related to poor bioavailability or
to lack of efﬁcacy against the isolate, as hypothesized by the
authors, remains unclear. Clearly, further studies are war-
ranted to evaluate combined antifungal and iron chelation
therapy in patients with invasive zygomycosis and to assess
the safety of this approach.
Conclusions
Because of the poor prognosis of zygomycosis, particularly in
immunocompromised cancer patients, adjunctive treatments
such as HBOT, use of immunomodulatory cytokines, and in
vivo iron starvation continue to be explored. However,
although each of these modalities has a plausible scientiﬁc
rationale and has been helpful in the management of individ-
ual patients, there is no clinical evidence for their general
effectiveness as adjunctive treatments in patients with zygo-
mycosis. Further experimental and clinical investigations are
necessary to determine whether and how these treatments
can with which impact on outcome and to determine which
patients, infections, may beneﬁt from them.
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